Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Otonomy Inc    OTIC

OTONOMY INC (OTIC)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/05/2017 12/06/2017 12/07/2017 12/08/2017 12/11/2017 Date
5.1(c) 5(c) 4.95(c) 5.05(c) 4.95(c) Last
329 926 1 043 157 525 188 395 025 505 694 Volume
0.00% -1.96% -1.00% +2.02% -1.98% Change
More quotes
Financials ($)
Sales 2017 1,46 M
EBIT 2017 -92,8 M
Net income 2017 -91,3 M
Finance 2017 54,0 M
Yield 2017 -
Sales 2018 7,90 M
EBIT 2018 -70,8 M
Net income 2018 -70,2 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 66,1x
Capi. / Sales2018 19,0x
Capitalization 150 M
More Financials
Company
Otonomy, Inc. engages in the research, development, and manufacture of biopharmaceutical products.The company portfolio includes therapeutics for diseases and disorders of the ear such as otitis media, acute otitis externa, balance disorders, Ménière's disease, tinnitus, cisplatin-induced hearing... 
More about the company
Surperformance© ratings of Otonomy Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on OTONOMY INC
11/29 OTONOMY : Announces Plan to Focus on Development of Drug for Ménière’s Dis..
11/28 OTONOMY : Announces Plan to Focus Resources on Development Programs
11/28 OTONOMY, INC. (NASDAQ : OTIC) Files An 8-K Costs Associated with Exit or Disposa..
11/27 OTONOMY, INC. : Costs Associated with Exit or Disposal Activities, Financial Sta..
11/27 Otonomy Announces Plan to Focus Resources on Development Programs
11/24 OTONOMY : to Present at Piper Jaffray Healthcare Conference
11/22 Otonomy to Present at Piper Jaffray Healthcare Conference
11/14 OTONOMY : Reports Third Quarter 2017 Financial Results and Provides Corporate Up..
11/14 OTONOMY : Reports Positive Results from AVERTS-2 Phase 3 Trial of OTIVIDEX in Pa..
11/09 OTONOMY : Rallies on Phase 3 Study of Otividex for Ménière's Disease
More news
Sector news : Bio Therapeutic Drugs
10:43a M&A dominates Europe share trading as oil leads gains
12/09 Tax-loss selling to pressure 2017's losers in December
11/30 GENMAB : and J&J 'love' partnership as some ponder takeover
11/27 MERCK AND : As Brexit looms, UK pitches new industry plan, wins support from Mer..
11/27 MERCK AND : As Brexit looms, UK pitches new industry plan, wins support from Mer..
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
12/11 NASDAQ BIOTECH INDEX : 54 to be added, 15 removed
11/28 PREMARKET GAINERS AS OF 9 : 05 am
11/27 Otonomy drops support for Otiprio to sharpen focus on pipeline development; s..
11/10 Otonomy's (OTIC) CEO David Weber on Q3 2017 Results - Earnings Call Transcrip..
11/10 Otonomy 2017 Q3 - Results - Earnings Call Slides
Chart OTONOMY INC
Duration : Period :
Otonomy Inc Technical Analysis Chart | OTIC | US68906L1052 | 4-Traders
Technical analysis trends OTONOMY INC
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 9,75 $
Spread / Average Target 97%
EPS Revisions
Managers
NameTitle
David A. Weber President, Chief Executive Officer & Director
Jay B. Lichter Chairman
Paul E. Cayer Chief Financial, Business & Accounting Officer
Robert Michael Savel Chief Technical Officer
Dean Hakanson Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
OTONOMY INC-68.87%150
GILEAD SCIENCES1.55%99 094
REGENERON PHARMACEUTICALS1.78%40 969
VERTEX PHARMACEUTICALS88.38%35 831
GENMAB1.79%11 452
BLUEBIRD BIO INC172.12%9 249